Late-breaking poster presentations (as of 9/20/23)

Poster Session B
Friday, October 13 | 12:30 pm-4:00 pm
Level 2, Exhibit Hall D

LB_B01: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRAS\textsuperscript{G12C}(ON) inhibitor, in patients with or without prior KRAS\textsuperscript{G12C}(OFF) inhibitor treatment. Pasi A. Jänne, Dana Farber Cancer Institute, Boston, MA United States.

LB_B02: Novel PAMs from somatic mutations produce numerous pancreatic cancer-specific CRISPR-Cas9 targets for selective cell elimination: A novel gene therapy approach for cancer. Selina Shiqing K. Teh, The Johns Hopkins University School of Medicine, Baltimore, MD United States.

LB_B03: Lentivirus-induced ALDH1L1 knock-in inhibits proliferation and migration and activates apoptosis of human A549 lung adenocarcinoma cells. Amira A. Abdellatef, Nutrition Research Institute, University of North Carolina at Chapel Hill, Kannapolis, NC United States.

LB_B04: Deciphering FGFR3-TACC3 oncogenic fusions. Julia Yemelyanenko, Netherlands Cancer Institute, Amsterdam, Netherlands.

LB_B05: Mapping therapy resistant phenotypes in SCLC liquid biopsies with single-cell proteomics at a personalized level. Loukia G. Karacosta, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

LB_B06: Single cell transcriptomics guided identification of antigen combinations for the design of logic-gated CAR therapies. Sanna Madan, National Cancer Institute, Bethesda, MD United States.

LB_B07: Probability of negative impact on adherence caused by the most frequent side effects of adjuvant endocrine therapy for premenopausal breast cancer in SOFT and TEXT Trials. Tariq Hassan AL Qurayshah, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.

LB_B08: The SRG OncoRat supports tumors derived from several RAS mutant cell lines for pre-clinical testing of RAS-inhibitors. Grace Walton, Hera BioLabs, Lexington, KY United States.

LB_B09: Loss of folate enzyme ALDH1L1 promotes cancer cell proliferation and xenograft tumor growth. Halle M. Fogle, University of North Carolina- Chapel Hill- Nutrition Department, Kannapolis, NC United States.


LB_B11: Transmembrane chloride intracellular channel 1 (tmCLIC1) protein as a key regulator of colorectal cancers' aggressiveness. Francesca Cianci, Università di Milano, Milan, Italy.

LB_B12: Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION I). Candace Haddox, Dana-Farber Cancer Institute, Boston, MA United States.
LB_B14: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors. Jordi Rodon, MD Anderson Cancer Center, Houston, TX United States.

LB_B15: The antiproliferative activity of metformin in glioblastoma stem cells is mediated by the direct binding and functional inhibition of the membrane configuration of CLIC1 protein. Michele M. Mazzanti, University of Milano, Milano, Italy.


LB_B17: Single-cell analysis of dynamic remodeling of radiated TNBC cells. Minhee Ku, Yonsei University, Seoul, Korea, Republic of.

LB_B18: Rapid and Reproducible Scaffold Free Organoid Formation for Personalized Medicine: Multiomic Analysis of In-Vitro Cancer Patient Model. Ying-Chih Chang, Acrocyte Therapeutics, Taipei, Taiwan (Greater China).

LB_B19: Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 inhibitor treatment for chordoma patients. Jianfei Yang, Turing-Darwin Laboratory, Beijing, China (Mainland).

LB_B20: The Unity Theory of One: The dynamic algorithm of mass action law for drug and biosimilar digital evaluation/simulation in molecules, cells, and organs, regardless of units, physical states, and mechanisms. Ting-Chao Chou, PD Science LLC (USA), Paramus, NJ United States.

LB_B21: Extracellular RNA signatures of mutant KRAS-driven lung cancer. Sree lakshmi Velandi Maroli, University of California, Santa Cruz, Santa Cruz, CA United States.


LB_B23: Magnetospirillum magneticum promotes iron competition and triggers apoptosis in human cancer cells. Stefano Menghini, ETHZ, Zurich, Switzerland.

LB_B24: Validating novel therapeutic antibodies for targeting head & neck squamous cell malignancies. Ameer S. Basta, USF Health Morsani College of Medicine, Tampa, FL United States.


LB_B26: Efficacy and tolerability of a novel pan-RAS inhibitor with a unique mechanism of selectivity in mouse models of pancreatic cancer. Gary A. Piazza, Auburn University Harrison College of Pharmacy, Auburn, AL United States.